Amivantamab, the first epidermal growth factor receptor and mesenchymal–epithelial transition factor inhibitor, associated with penile and inguinal ulcers and paronychia

• Karina J. Cancel-Artau, MD,
• Angélica C. Marrero-Pérez, MD,
• Eduardo A. Michelén-Gómez, MD,
• Xavier Sánchez-Flores, MD

Affiliations

Karina J. Cancel-Artau, MD

Department of Dermatology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico; Correspondence to: Karina J. Cancel-Artau, MD, Department of Dermatology, University of Puerto Rico School of Medicine, PO Box 365067, San Juan, PR 00936-5067.

Angélica C. Marrero-Pérez, MD

University of Medicine and Health Sciences, Basseterre, Saint Kitts and Nevis

Eduardo A. Michelén-Gómez, MD

Department of Dermatology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico

Xavier Sánchez-Flores, MD

Department of Dermatology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico